Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial

Keyphrases

• Randomized Placebo-controlled Trial 100%
• Phase II Trial 100%
• Relapsing-remitting multiple Sclerosis 100%
• Opicinumab 100%
• Placebo 33%
• Disability Improvement 16%
• Adverse Events 11%
• Placebo Groups 5%
• Randomized Double-blind 5%
• Placebo-controlled 5%
• Headache 5%
• Demyelination 5%
• Monoclonal Antibody 5%
• Disability 5%
• Phase II Study 5%
• Axonal Regeneration 5%
• Urinary Tract Infection 5%
• Serious Adverse Events 5%
• Influenza-like Illness 5%
• Bipolar Disorder 5%
• Patient Visits 5%
• Progressive multiple Sclerosis 5%
• Suicidal Ideation 5%
• Anti-inflammatory Therapy 5%
• Expanded Disability Status Scale 5%
• Dose-ranging 5%
• Nine-hole Peg Test 5%
• Response System 5%
• Timed 25-Foot Walk 5%
• Linear Trend 5%
• CNS Demyelinating Disease 5%
• Trend Test 5%
• Voice User Interface 5%
• Intentional Overdose 5%
• Paced Auditory Serial Addition Test (PASAT) 5%
• Traffic Accidents 5%
• Oligodendrocyte Differentiation 5%
• Interferon beta-1a 5%
• Multiple Sclerosis Relapse 5%
• Interactive Web Response 5%
• Linear Dose Response 5%
• Lingo 5%
• Intention-to-treat Principle 5%
• Biogen 5%

Pharmacology, Toxicology and Pharmaceutical Science

• Placebo 100%
• Multiple Sclerosis 100%
• Opicinumab 100%
• Adverse Event 16%
• Headache 5%
• Urinary Tract Infection 5%
• Toxic Injury 5%
• Anti-Inflammatory Drug 5%
• Flu Like Syndrome 5%
• Bipolar Disorder 5%
• Erethism 5%
• Expanded Disability Status Scale 5%
• Recombinant Gamma Interferon 5%
• Human Monoclonal Antibody 5%
• Beta1a Interferon 5%
• Diseases 5%
• Suicidal Ideation 5%